Drug intelligence / Profile preview

AS1701

Development stage: Preclinical
Lead developer: Zhongke Aishen Pharmaceutical

Overview

AS1701 is a preclinical-stage biologic blocker developed by Zhongke Aishen Pharmaceutical (Amshenn) that targets the Rel immune checkpoint. Positioned as a next-generation successor to the company's AS1601 program, AS1701 is designed to inhibit Rel-mediated immunosuppression within the tumor microenvironment. The agent is intended for the treatment of solid tumors, either as a standalone therapy or in combination with PD-1 blockade to overcome resistance and improve clinical outcomes. It is currently in the efficacy exploration stage of development.

Other names: Rel blocker

Targets

REL (Proto-oncogene c-Rel)

Beyond the preview

Go deeper on AS1701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS1701.

Explore the full profile